360Dx recently published an article on novel approaches in tuberculosis (TB) diagnostics, titled "As Novel Approaches Drive TB Testing Expansion, Global Goal of Disease Eradication Remains Elusive" (19 November 2025). The piece reviews global progress toward expanding access to TB testing and discusses emerging molecular tools, including swab-based methods and near point-of-care solutions.
In the article, Adithya Cattamanchi and a team of international collaborators report an evaluation of the Pluslife MiniDock TB test and Molbio MTB Ultima using sputum swabs and tongue swabs. The Pluslife MiniDock TB test is described as a near point-of-care assay, and MiniDock is characterized as a highly portable, battery operable system that is "expected to be much lower cost than current low-complexity sputum-based molecular tests." The article further notes that MiniDock "potentially helps fill the gap that the Cepheid Omni was intended to fill before it was discontinued a few years ago" and quotes Cattamanchi describing it as "a major advance that should improve access to TB testing."
Pluslife welcomes this independent coverage of the MiniDock TB test within the broader landscape of TB diagnostic innovation. The company remains committed to advancing practical near-POC molecular diagnostics that bring reliable TB testing closer to patients and support global efforts to address current TB diagnostic gaps.
For more details, please refer to the original 360Dx article:
"As Novel Approaches Drive TB Testing Expansion, Global Goal of Disease Eradication Remains Elusive," 360Dx, 19 November 2025.
